Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019–2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
Journal
International journal of antimicrobial agents
Journal Volume
58
Journal Issue
1
Date Issued
2021-07
Author(s)
Tsai, Hsih-Yeh
Lee, Yu-Lin
Liu, Po-Yu
Lu, Min-Chi
Lu, Po-Liang
Cheng, Shu-Hsing
Ko, Wen-Chien
Lin, Chi-Ying
Wu, Ting-Shu
Yen, Muh-Yong
Wang, Lih-Shinn
Liu, Chang-Pan
Lee, Wen-Sen
Shi, Zhi-Yuan
Chen, Yao-Shen
Wang, Fu-Der
Tseng, Shu-Hui
Chen, Yu-Hui
Lee, Chun-Ming
Chen, Yen-Hsu
Liao, Chun-Hsing
Abstract
Multicenter surveillance of antimicrobial susceptibility was performed for 235 vancomycin-resistant Enterococcus faecium (VREfm) isolates from 18 Taiwanese hospitals. The minimum inhibitory concentrations (MICs) of eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics were determined using the broth microdilution method. Nearly all isolates of VREfm were not susceptible to teicoplanin, dalbavancin, and telavancin, with susceptibility rates of 0.5%, 1.7% and 0.5%, respectively. Tigecycline and eravacycline were active against 93.2% and 89.7% of the VREfm isolates, respectively. Moreover, the susceptibility rates of quinupristin/dalfopristin, tedizolid, and linezolid were 59.1%, 84.2%, and 77.4%, respectively. Additionally, 94% of the VREfm isolates were classified as susceptible to daptomycin, and the MICs of omadacycline required to inhibit VREfm growth by 50% and 90% were 0.12 and 0.5 mg/L, respectively. Susceptibility rates of VREfm isolates to synthetic tetracyclines and daptomycin were slightly lower and to oxazolidinone-class antibiotics were much lower in Taiwan than those in other parts of the world. Continuous monitoring of VREfm resistance to novel antibiotics, including synthetic tetracyclines, oxazolidinone-class antibiotics, and daptomycin, is needed in Taiwan.
Subjects
Eravacycline; Lipoglycopeptides; Omadacycline; Tedizolid; Vancomycin-resistant Enterococcus faecium
Type
journal article